What is STEC and how does it differ from ordinary E. coli?

Shiga toxin-producing E. coli (STEC) is a subset of E. coli bacteria that produce Shiga toxins (Stx) — potent toxins that can cause life-threatening haemolytic uraemic syndrome (HUS). Regular E. coli (commensal E. coli in the gut) do not produce Shiga toxins and are harmless. STEC O157:H7 was first recognised as a human pathogen in 1982 during hamburger-associated outbreaks in the US. It lives harmlessly in cattle intestines (cattle are the natural reservoir) and contaminates meat during slaughter or the environment through faecal runoff.

What are the symptoms of STEC infection?

Incubation: 3-4 days (range 1-10 days). Initial symptoms: sudden onset watery diarrhoea, severe abdominal cramps, low-grade fever. 24-72 hours later: diarrhoea often becomes bloody (haemorrhagic colitis) — sometimes described as "all blood, no stool" in severe cases. High fever is ABSENT or mild (this distinguishes STEC haemorrhagic colitis from bacterial dysentery from Shigella, which has fever). In 5-15% of cases (mostly children <5): HUS begins 5-10 days after diarrhoea onset — pallor, reduced urine output, easy bruising, lethargy.

Why are antibiotics absolutely contraindicated?

Giving antibiotics (particularly fluoroquinolones like ciprofloxacin, or TMP-SMX) in suspected STEC O157 infection is contraindicated because: they stress the bacteria, triggering the SOS DNA damage response → upregulation of the bacteriophage carrying the Shiga toxin gene → massive increase in Stx release → much higher Stx blood levels → dramatically increased HUS risk. Multiple clinical studies and a Cochrane review confirm: antibiotics approximately double the risk of HUS in STEC O157 infection. Therefore: if STEC is suspected or confirmed — NO antibiotics (regardless of how sick the patient looks from the diarrhoea).

How is STEC infection managed?

Supportive care is the cornerstone: oral rehydration therapy for mild cases; IV hydration for moderate-severe dehydration; careful fluid balance monitoring (vital in early HUS — aggressive hydration reduces HUS severity). NO antibiotics. NO loperamide (antidiarrhoeals increase HUS risk by prolonging toxin exposure). Monitor: FBC (platelet count — falling platelets signal HUS); renal function (rising creatinine/urea); urine output. Refer urgently to paediatric nephrology if HUS develops. HUS treatment: RRT (dialysis or continuous renal replacement) when needed; plasma exchange for severe cases; transfuse packed red cells (not platelets, unless life-threatening bleeding).

What are the most important outbreak sources?

Historically: undercooked ground beef (hamburgers) — the first recognised vehicle (1982 Jack in the Box outbreak); raw/unpasteurised milk; fermented dry-cured meats (salami, mettwurst). More recently: raw sprouts (2011 Germany O104:H4); leafy greens (spinach — 2006 US outbreak); apple cider; petting zoo animal contact (direct faecal-oral); contaminated water (paddling pools, streams). Prevention: cook ground beef to ≥71°C internal temperature; pasteurise milk; wash produce thoroughly; hand hygiene after animal contact.

How does GMJ News cover STEC?

GMJ News covers ECDC STEC mandatory surveillance, the antibiotic contraindication (the most critical clinical rule), HUS pathophysiology, the 2011 Germany landmark outbreak, beef and produce as vehicles, sorbitol MacConkey agar diagnosis, and the EFSA One Health zoonoses data. STEC — with its lethal antibiotic-contraindication rule — is directly relevant to PHIG's food safety programme and clinical training priorities.

Home › Topics › STEC (Shiga-toxin-producing E. coli)

STEC (Shiga-toxin-producing E. coli)

Q: Why are antibiotics absolutely contraindicated?

Giving antibiotics (particularly fluoroquinolones like ciprofloxacin, or TMP-SMX) in suspected STEC O157 infection is contraindicated because: they stress the bacteria, triggering the SOS DNA damage response → upregulation of the bacteriophage carrying the Shiga toxin gene → massive increase in Stx release → much higher Stx blood levels → dramatically increased HUS risk. Multiple clinical studies and a Cochrane review confirm: antibiotics approximately double the risk of HUS in STEC O157 infection. Therefore: if STEC is suspected or confirmed — NO antibiotics (regardless of how sick the patient looks from the diarrhoea).

Q: How is STEC infection managed?

Supportive care is the cornerstone: oral rehydration therapy for mild cases; IV hydration for moderate-severe dehydration; careful fluid balance monitoring (vital in early HUS — aggressive hydration reduces HUS severity). NO antibiotics. NO loperamide (antidiarrhoeals increase HUS risk by prolonging toxin exposure). Monitor: FBC (platelet count — falling platelets signal HUS); renal function (rising creatinine/urea); urine output. Refer urgently to paediatric nephrology if HUS develops. HUS treatment: RRT (dialysis or continuous renal replacement) when needed; plasma exchange for severe cases; transfuse packed red cells (not platelets, unless life-threatening bleeding).

Q: What are the most important outbreak sources?

Historically: undercooked ground beef (hamburgers) — the first recognised vehicle (1982 Jack in the Box outbreak); raw/unpasteurised milk; fermented dry-cured meats (salami, mettwurst). More recently: raw sprouts (2011 Germany O104:H4); leafy greens (spinach — 2006 US outbreak); apple cider; petting zoo animal contact (direct faecal-oral); contaminated water (paddling pools, streams). Prevention: cook ground beef to ≥71°C internal temperature; pasteurise milk; wash produce thoroughly; hand hygiene after animal contact.

Q: How does GMJ News cover STEC?

GMJ News covers ECDC STEC mandatory surveillance, the antibiotic contraindication (the most critical clinical rule), HUS pathophysiology, the 2011 Germany landmark outbreak, beef and produce as vehicles, sorbitol MacConkey agar diagnosis, and the EFSA One Health zoonoses data. STEC — with its lethal antibiotic-contraindication rule — is directly relevant to PHIG's food safety programme and clinical training priorities.

GMJ News knowledge hub · last reviewed September 2026 · Georgian Medical Journal

Summary Statistics Glossary GMJ news FAQ Documents Organizations Research

Shiga toxin-producing Escherichia coli (STEC) — particularly the O157:H7 serotype and non-O157 serogroups (O26, O111, O103, O145) — is a food-borne pathogen with a uniquely dangerous complication: approximately 5-15% of STEC O157 infections progress to haemolytic uraemic syndrome (HUS) — a life-threatening triad of microangiopathic haemolytic anaemia, thrombocytopenia and acute kidney injury — predominantly in children under 5, making it the most common cause of acute kidney failure in children in high-income countries (WHO). A critical clinical rule: antibiotics are contraindicated in suspected STEC O157 infection — they increase Shiga toxin release and double or triple the risk of HUS. The 2011 Germany outbreak (E. coli O104:H4 from sprouted seeds — 3,800 cases, 54 deaths, 845 HUS) remains the largest ever HUS outbreak.

Key messages

DO NOT give antibiotics — doubles HUS risk

This is the most critical clinical rule in STEC management: antibiotics (particularly fluoroquinolones and TMP-SMX) increase Shiga toxin (Stx) release and are associated with a 2-3 fold increase in haemolytic uraemic syndrome (HUS) risk. Antibiotics are absolutely contraindicated in suspected STEC O157 infection.

5-15% develop HUS — children most vulnerable

Approximately 5-15% of STEC O157 infections progress to haemolytic uraemic syndrome (HUS) — particularly in children under 5 and the elderly. HUS is the most common cause of acute kidney failure in children in high-income countries.

Undercooked beef and raw milk — primary sources

STEC O157 lives harmlessly in cattle intestines. Primary human exposure: undercooked ground beef (hamburgers — the first major outbreak vehicle); raw/unpasteurised milk; raw produce contaminated with cattle faeces (spinach, sprouts, lettuce); petting zoo animal contact; contaminated drinking water.

Lowest infectious dose of any foodborne pathogen — 10-100 organisms

STEC requires as few as 10-100 organisms to cause infection — among the lowest infectious doses of any known foodborne pathogen. This explains how seemingly minor contamination (a drop of beef juice) or person-to-person spread can initiate outbreaks.

ECDC mandatory surveillance + EFSA One Health

STEC is ECDC mandatory notifiable disease and EFSA mandatory zoonosis under the EU One Health framework. EU One Health 2024 Zoonoses Report: STEC is among the six mandatory monitoring pathogens in food and animals.

2011 Germany — largest HUS outbreak ever

The 2011 Germany E. coli O104:H4 outbreak (from sprouted fenugreek seeds) caused 3,842 cases and 54 deaths including 845 HUS cases — the largest STEC/HUS outbreak ever recorded. Unlike O157, this strain produced Stx and also had an aggregative virulence plasmid — a one-time hybrid.

Key statistics

5-15%

of STEC O157 infections develop HUS (predominantly children <5)

WHO/CDC

10-100

organisms sufficient to cause STEC infection (extremely low ID50)

WHO

benefit from antibiotics in STEC O157 — contraindicated

WHO/Cochrane

2011

Germany O104:H4 outbreak — 3,842 cases, 54 deaths, 845 HUS

ECDC/2011

Mandatory

ECDC notifiable disease and EFSA One Health priority zoonosis

ECDC/EFSA

cause of acute kidney failure in children in HICs (via HUS)

WHO

STEC O157 infection outcomes — progression from infection to HUS

Source: WHO/CDC. Most STEC infections are self-limiting; 5-15% develop HUS; HUS mortality approximately 1-5%.

Glossary of key terms

STEC and non-O157 serogroups
WHO/ECDCShiga toxin-producing E. coli encompasses O157:H7 and multiple non-O157 serogroups (O26, O103, O111, O121, O145 — the "top 6" non-O157 STEC serogroups causing human disease). Non-O157 STEC can cause HUS but typically at lower rates than O157. Detection requires specific testing (Shiga toxin EIA or PCR) as non-O157 strains do not produce the distinctive metallic-smell colonies on sorbitol MacConkey agar.

Shiga toxins (Stx1 and Stx2)
WHOAB5 toxins produced by STEC — homologous to Shiga toxin from Shigella dysenteriae type 1. Stx2 is more potent and more strongly associated with HUS. Mechanism: B subunit binds to Gb3 glycolipid receptor (highly expressed on renal glomerular endothelial cells and neural cells) → A subunit inhibits protein synthesis (RNA N-glycosidase — cleaves 28S rRNA) → endothelial cell death → microangiopathic thrombosis → HUS.

HUS (haemolytic uraemic syndrome)
WHOThe classic HUS triad: microangiopathic haemolytic anaemia (from red cell destruction in damaged small vessels — schistocytes on blood film); thrombocytopenia (from platelet consumption in microvascular thrombi); acute kidney injury (from glomerular endothelial damage). Typically in children, 5-10 days after onset of diarrhoea. Treatment: supportive — fluid management, renal replacement therapy (RRT) when needed; plasma exchange (for atypical HUS — complement-mediated, not Stx-related); eculizumab (anti-C5) for severe/atypical HUS.

Antibiotic contraindication mechanism
WHO/NEJMBeta-lactam antibiotics (ampicillin) and fluoroquinolones (ciprofloxacin) induce the SOS DNA damage response in E. coli, which upregulates the bacteriophage carrying the Shiga toxin gene — dramatically increasing Stx production and release. A meta-analysis and multiple clinical series show that antibiotic use in STEC O157 infection is associated with 2-3 fold increased HUS risk. This remains one of the most important "do not do" rules in clinical infectious disease.

Sorbitol MacConkey agar (SMAC)
WHO/MicrobiologyThe selective culture medium for STEC O157:H7 — E. coli O157 cannot ferment sorbitol (unlike most E. coli) and appears as colourless/non-fermenting colonies on SMAC, which are then confirmed by latex agglutination. Non-O157 STEC ferments sorbitol (appears pink on SMAC) and requires Shiga toxin ELISA or PCR for detection.

Eculizumab in HUS
FDA/EMAEculizumab (Soliris) — a monoclonal antibody against complement component C5 — is licensed for atypical HUS (aHUS, caused by complement dysregulation) and has been used off-label in some severe Stx-HUS cases. Evidence for its use in Stx-HUS is limited; it was used extensively in the 2011 Germany outbreak without clear benefit over supportive care. It remains standard of care for aHUS, not typical STEC-HUS.